Montelukast, current indications and prospective future applications

References

• Masoli M, Fabian D, Holt S, et al. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy. 2004;59(5):469–478.
   PubMed Web of Science ®Google Scholar
• Myers TR, Tomasio L. Asthma: 2015 and beyond. Respir Care. 2011;56(9):1389–1407;discussion 1407–1310.
   PubMed Web of Science ®Google Scholar
• Olin JT, Wechsler ME. Asthma: pathogenesis and novel drugs for treatment. BMJ. 2014;349:g5517.
   PubMed Web of Science ®Google Scholar
• Ogawa Y, Calhoun WJ. The role of leukotrienes in airway inflammation. J Allergy Clin Immunol. 2006;118(4):789–798; quiz 799–800.
   PubMed Web of Science ®Google Scholar
• O’Byrne PM. Leukotriene bronchoconstriction induced by allergen and exercise. Am J Respir Crit Care Med. 2000;161(2 Pt 2):S68–S72.
   PubMed Web of Science ®Google Scholar
• Meltzer SS, Hasday JD, Cohn J, et al. Inhibition of exercise-induced bronchospasm by zileuton: a 5-lipoxygenase inhibitor. Am J Respir Crit Care Med. 1996;153(3):931–935.
   PubMed Web of Science ®Google Scholar
• Israel E, Dermarkarian R, Rosenberg M, et al. The effects of a 5-lipoxygenase inhibitor on asthma induced by cold, dry air. N Engl J Med. 1990;323(25):1740–1744.
   PubMed Web of Science ®Google Scholar
• Giavi S, Papadopoulos NG. Asthma control in adolescents: role of leukotriene inhibitors. Adolesc Health Med Ther. 2010;1:129–136.
   PubMedGoogle Scholar
• Drazen J. Clinical pharmacology of leukotriene receptor antagonists and 5-lipoxygenase inhibitors. Am J Respir Crit Care Med. 1998;157(6 Pt 2):S233–S237; discussion S247–S238.
   Web of Science ®Google Scholar
• Cingi C, Muluk NB, Ipci K, et al. Antileukotrienes in upper airway inflammatory diseases. Curr Allergy Asthma Rep. 2015;15(11):64.
   PubMed Web of Science ®Google Scholar
• Walia M, Lodha R, Kabra SK. Montelukast in pediatric asthma management. Indian J Pediatr. 2006;73(4):275–282.
   PubMedGoogle Scholar
• Amlani S, Nadarajah T, McIvor RA. Montelukast for the treatment of asthma in the adult population. Expert Opin Pharmacother. 2011;12(13):2119–2128.
   PubMed Web of Science ®Google Scholar
• O’Byrne PM. Antileukotrienes, asthma pathogenesis and the pharmaceutical industry. CMAJ. 1999;160(2):209–210.
   PubMed Web of Science ®Google Scholar
• Wahn U, Dass SB. Review of recent results of montelukast use as a monotherapy in children with mild asthma. Clin Ther. 2008;30 Spec No:1026–1035.
   PubMed Web of Science ®Google Scholar
• Papadopoulos G, Kuhly P, Brock M, et al. [Postoperative air embolism caused by pneumatocephalus following occlusion of the posterior fossa. A rare complication indicative of a bridging vein disruption]. Anaesthesist. 1993;42(9):648–651.
   PubMed Web of Science ®Google Scholar
• Reiss TF, Chervinsky P, Dockhorn RJ, et al. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group. Arch Intern Med. 1998;158(11):1213–1220.
   PubMed Web of Science ®Google Scholar
• Knorr B, Matz J, Bernstein JA, et al. Montelukast for chronic asthma in 6- to 14-year-old children: a randomized, double-blind trial. Pediatric Montelukast Study Group. JAMA. 1998;279(15):1181–1186.
   PubMed Web of Science ®Google Scholar
• Spahn JD, Covar RA, Jain N, et al. Effect of montelukast on peripheral airflow obstruction in children with asthma. Ann Allergy Asthma Immunol. 2006;96(4):541–549.
   PubMed Web of Science ®Google Scholar
• Bhatt JM, Smyth AR. The management of pre-school wheeze. Paediatr Respir Rev. 2011;12(1):70–77.
   PubMed Web of Science ®Google Scholar
• Kemp JP, Dockhorn RJ, Shapiro GG, et al. Montelukast once daily inhibits exercise-induced bronchoconstriction in 6- to 14-year-old children with asthma. J Pediatr. 1998;133(3):424–428.
   PubMed Web of Science ®Google Scholar
• Kim JH, Lee SY, Kim HB, et al. Prolonged effect of montelukast in asthmatic children with exercise-induced bronchoconstriction. Pediatr Pulmonol. 2005;39(2):162–166.
   PubMed Web of Science ®Google Scholar
• Zhang HP, Jia CE, Lv Y, et al. Montelukast for prevention and treatment of asthma exacerbations in adults: systematic review and meta-analysis. Allergy Asthma Proc. 2014;35(4):278–287.
   PubMed Web of Science ®Google Scholar
• Tintinger GR, Feldman C, Theron AJ, et al. Montelukast: more than a cysteinyl leukotriene receptor antagonist? ScientificWorldJournal. 2010;10:2403–2413.
   PubMed Web of Science ®Google Scholar
• Becher UM, Ghanem A, Tiyerili V, et al. Inhibition of leukotriene C4 action reduces oxidative stress and apoptosis in cardiomyocytes and impedes remodeling after myocardial injury. J Mol Cell Cardiol. 2011;50(3):570–577.
   PubMed Web of Science ®Google Scholar
• Abdel-Raheem IT, Khedr NF. Renoprotective effects of montelukast, a cysteinyl leukotriene receptor antagonist, against methotrexate-induced kidney damage in rats. Naunyn-Schmiedeberg’s Arch Pharmacol. 2014;387(4):341–353.
   Google Scholar
• Lafci G, Gedik HS, Korkmaz K, et al. Efficacy of iloprost and montelukast combination on spinal cord ischemia/reperfusion injury in a rat model. J Cardiothorac Surg. 2013;8:64.
   PubMed Web of Science ®Google Scholar
• Zhou C, Shi X, Huang H, et al. Montelukast attenuates neuropathic pain through inhibiting p38 mitogen-activated protein kinase and nuclear factor-kappa B in a rat model of chronic constriction injury. Anesth Analg. 2014;118(5):1090–1096.
   PubMed Web of Science ®Google Scholar
• Lai J, Mei ZL, Wang H, et al. Montelukast rescues primary neurons against Abeta1-42-induced toxicity through inhibiting CysLT1R-mediated NF-kappaB signaling. Neurochem Int. 2014;75:26–31.
   PubMed Web of Science ®Google Scholar
• Cavus G, Altas M, Aras M, et al. Effects of montelukast and methylprednisolone on experimental spinal cord injury in rats. Eur Rev Med Pharmacol Sci. 2014;18(12):1770–1777.
   PubMed Web of Science ®Google Scholar
• Shin IS, Jeon WY, Shin HK, et al. Effects of montelukast on subepithelial/peribronchial fibrosis in a murine model of ovalbumin induced chronic asthma. Int Immunopharmacol. 2013;17(3):867–873.
   PubMed Web of Science ®Google Scholar
• Roth FD, Quintar AA, Leimgruber C, et al. Restoration of the normal Clara cell phenotype after chronic allergic inflammation. Int J Exp Pathol. 2013;94(6):399–411.
   PubMed Web of Science ®Google Scholar
• Gobbato NB, de Souza FC, Fumagalli SB, et al. Antileukotriene reverts the early effects of inflammatory response of distal parenchyma in experimental chronic allergic inflammation. Biomed Res Int. 2013;2013:523761.
   PubMed Web of Science ®Google Scholar
• Wei B, Shang YX, Li M, et al. [Effect of montelukast on the expression of neurokinin-1 receptor in young asthmatic rats with airway remodeling]. Zhongguo dang dai er ke za zhi = Chin J Contemp Pediatr. 2013;15(4):298–301.
   PubMedGoogle Scholar
• Muraki M, Imbe S, Santo H, et al. Effects of a cysteinyl leukotriene dual 1/2 receptor antagonist on antigen-induced airway hypersensitivity and airway inflammation in a guinea pig asthma model. Int Arch Allergy Immunol. 2011;155(Suppl 1):90–95.
   PubMed Web of Science ®Google Scholar
• Ikeda G, Miyahara N, Koga H, et al. Effect of a cysteinyl leukotriene receptor antagonist on experimental emphysema and asthma combined with emphysema. Am J Respir Cell Mol Biol. 2014;50(1):18–29.
   PubMed Web of Science ®Google Scholar
• Bozkurt MK, Tulek B, Bozkurt B, et al. Comparison of the efficacy of prednisolone, montelukast, and omalizumab in an experimental allergic rhinitis model. Turk J Med Sci. 2014;44(3):439–447.
   PubMed Web of Science ®Google Scholar
• Otunctemur A, Ozbek E, Cakir SS, et al. Beneficial effects montelukast, cysteinyl-leukotriene receptor antagonist, on renal damage after unilateral ureteral obstruction in rats. Int Braz J Urol. 2015;41(2):279–287.
   PubMed Web of Science ®Google Scholar
• Sunay M, Karakan T, Aydin A, et al. Do montelukast sodium and N-acetylcysteine have a nephroprotective effect on unilateral ureteral obstruction? A placebo controlled trial in a rat model. J Urol. 2015;194(4):1132–1137.
   PubMed Web of Science ®Google Scholar
• Otunctemur A, Ozbek E, Cekmen M, et al. Protective effect of montelukast which is cysteinyl-leukotriene receptor antagonist on gentamicin-induced nephrotoxicity and oxidative damage in rat kidney. Ren Fail. 2013;35(3):403–410.
   PubMed Web of Science ®Google Scholar
• Khodir AE, Ghoneim HA, Rahim MA, et al. Montelukast reduces sepsis-induced lung and renal injury in rats. Can J Physiol Pharmacol. 2014;92(10):839–847.
   PubMed Web of Science ®Google Scholar
• Ocak T, Duran A, Ozyalvacli G, et al. Protective effects of montelukast and Hypericum perforatum against intestinal ischemia-reperfusion injury in hamsters. Turk J Med Sci. 2014;44(3):381–386.
   PubMed Web of Science ®Google Scholar
• Duran A, Otiuk H, Terzi EH, et al. Protective effect of montelukast, a cysteinyl leukotriene receptor-1 antagonist, against intestinal ischemia-reperfusion injury in the rat. Acta Chir Belg. 2013;113(6):401–405.
   PubMed Web of Science ®Google Scholar
• Saad MA, Abdelsalam RM, Kenawy SA, et al. Montelukast, a cysteinyl leukotriene receptor-1 antagonist protects against hippocampal injury induced by transient global cerebral ischemia and reperfusion in rats. Neurochem Res. 2015;40(1):139–150.
   PubMed Web of Science ®Google Scholar
• Xu DM, Zhang XY, Wang XR, et al. [Antioxidative effects of cysteinyl leukotriene receptor antagonists montelukast and HAMI 3379 on ischemic injury in rat cortical neurons in vitro]. hejiang da xue xue bao. Yi xue ban = J Zhejiang Univ Med Sci. 2014;43(3):257–264.
   PubMedGoogle Scholar
• Akdemir A, Erbas O, Ergenoglu M, et al. Montelukast prevents ischaemia/reperfusion-induced ovarian damage in rats. Eur J Obstet Gynecol Reprod Biol. 2014;173:71–76.
   PubMed Web of Science ®Google Scholar
• Zhang XY, Wang XR, Xu DM, et al. HAMI 3379, a CysLT2 receptor antagonist, attenuates ischemia-like neuronal injury by inhibiting microglial activation. J Pharmacol Exp Ther. 2013;346(2):328–341.
   PubMed Web of Science ®Google Scholar
• Zhang XY, Chen L, Yang Y, et al. Regulation of rotenone-induced microglial activation by 5-lipoxygenase and cysteinyl leukotriene receptor 1. Brain Res. 2014;1572:59–71.
   PubMed Web of Science ®Google Scholar
• Yu SY, Zhang XY, Wang XR, et al. Cysteinyl leukotriene receptor 1 mediates LTD4-induced activation of mouse microglial cells in vitro. Acta Pharmacol Sin. 2014;35(1):33–40.
   PubMed Web of Science ®Google Scholar
• Lai J, Hu M, Wang H, et al. Montelukast targeting the cysteinyl leukotriene receptor 1 ameliorates Abeta1-42-induced memory impairment and neuroinflammatory and apoptotic responses in mice. Neuropharmacology. 2014;79:707–714.
   PubMed Web of Science ®Google Scholar
• Lenz QF, Arroyo DS, Temp FR, et al. Cysteinyl leukotriene receptor (CysLT) antagonists decrease pentylenetetrazol-induced seizures and blood-brain barrier dysfunction. Neuroscience. 2014;277:859–871.
   PubMed Web of Science ®Google Scholar
• Cevik B, Solmaz V, Aksoy D, et al. Montelukast inhibits pentylenetetrazol-induced seizures in rats. Med Sci Monit. 2015;21:869–874.
   PubMed Web of Science ®Google Scholar
• Fleck J, Marafiga JR, Jesse AC, et al. Montelukast potentiates the anticonvulsant effect of phenobarbital in mice: an isobolographic analysis. Pharmacol Res. 2015;94:34–41.
   PubMed Web of Science ®Google Scholar
• Savari S, Liu M, Zhang Y, et al. CysLT(1)R antagonists inhibit tumor growth in a xenograft model of colon cancer. Plos One. 2013;8(9):e73466.
   PubMed Web of Science ®Google Scholar
• Jose MA, Amathi R, Sathyamurthy D, et al. Chemopreventive effect of montelukast in n-nitroso n-methyl urea induced mammary carcinogenesis in female Sprague-Dawley rats. Indian J Pharmacol. 2013;45(3):286–288.
   PubMed Web of Science ®Google Scholar
• Koca G, Yalniz-Akkaya Z, Gultekin SS, et al. Radioprotective effect of montelukast sodium in rat lacrimal glands after radioiodine treatment. Revista espanola de medicina nuclear e imagen molecular. 2013;32(5):294–300.
   PubMed Web of Science ®Google Scholar
• Koca G, Gultekin SS, Han U, et al. The efficacy of montelukast as a protective agent against 131I-induced salivary gland damage in rats: scintigraphic and histopathological findings. Nucl Med Commun. 2013;34(5):507–517.
   PubMed Web of Science ®Google Scholar
• Tien F-M, Wu J-F, Jeng Y-M, et al. Clinical features and treatment responses of children with eosinophilic gastroenteritis. Pediatrics Neonatal. 2011;52(5):272–278.
   PubMed Web of Science ®Google Scholar
• Nobili E, Salvado MD, Folkersen L, et al. Cysteinyl leukotriene signaling aggravates myocardial hypoxia in experimental atherosclerotic heart disease. Plos One. 2012;7(7):e41786.
   PubMed Web of Science ®Google Scholar
• Eskicioğlu F, Turan G, Sivrikoz O, et al. Montelukast is effective in preventing of ovarian hyperstimulation syndrome; an experimental study. Ginekologia polska. 2015;86(8):566–573.
   PubMed Web of Science ®Google Scholar
• Reiss TF, Altman LC, Chervinsky P, et al. Effects of montelukast (MK-0476), a new potent cysteinyl leukotriene (LTD4) receptor antagonist, in patients with chronic asthma. J Allergy Clin Immunol. 1996;98(3):528–534.
   PubMed Web of Science ®Google Scholar
• Reiss TF, Sorkness CA, Stricker W, et al. Effects of montelukast (MK-0476); a potent cysteinyl leukotriene receptor antagonist, on bronchodilation in asthmatic subjects treated with and without inhaled corticosteroids. Thorax. 1997;52(1):45–48.
   PubMed Web of Science ®Google Scholar
• Noonan MJ, Chervinsky P, Brandon M, et al. Montelukast, a potent leukotriene receptor antagonist, causes dose-related improvements in chronic asthma. Montelukast Asthma Study Group. Eur Respir J. 1998;11(6):1232–1239.
   PubMed Web of Science ®Google Scholar
• Altman LC, Munk Z, Seltzer J, et al. A placebo-controlled, dose-ranging study of montelukast, a cysteinyl leukotriene-receptor antagonist. Montelukast Asthma Study Group. J Allergy Clin Immunol. 1998;102(1):50–56.
   PubMed Web of Science ®Google Scholar
• Schlick W, Pohl W, Pfeiffer KP, et al. Evaluation of 3-5 months’ add-on therapy with montelukast in patients with non-controlled asthma in Austria: the STAR open-label, real-world, observational study. Curr Med Res Opin. 2010;26(3):561–570. .
   PubMed Web of Science ®Google Scholar
• Malmstrom K, Rodriguez-Gomez G, Guerra J, et al. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/Beclomethasone Study Group. Ann Intern Med. 1999;130(6):487–495.
   PubMed Web of Science ®Google Scholar
• Lofdahl CG, Reiss TF, Leff JA, et al. Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients. BMJ. 1999;319(7202):87–90.
   PubMed Web of Science ®Google Scholar
• Price D, Musgrave SD, Shepstone L, et al. Leukotriene antagonists as first-line or add-on asthma-controller therapy. N Engl J Med. 2011;364(18):1695–1707. .
   PubMed Web of Science ®Google Scholar
• Reiss TF, Hill JB, Harman E, et al. Increased urinary excretion of LTE4 after exercise and attenuation of exercise-induced bronchospasm by montelukast, a cysteinyl leukotriene receptor antagonist. Thorax. 1997;52(12):1030–1035. .
   PubMed Web of Science ®Google Scholar
• Knorr B, Franchi LM, Bisgaard H, et al. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics. 2001;108(3):E48.
   PubMed Web of Science ®Google Scholar
• Szefler SJ, Carlsson LG, Uryniak T, et al. Budesonide inhalation suspension versus montelukast in children aged 2 to 4 years with mild persistent asthma. J Allergy Clin Immunol Pract. 2013;1(1):58–64.
   PubMed Web of Science ®Google Scholar
• Amirav I. Real-life effectiveness of Singulair (montelukast) in 506 children with mild to moderate asthma. Isr Med Assoc J IMAJ. 2008;10(4):287–291.
   PubMed Web of Science ®Google Scholar
• Ferreira MB, Santos AS, Pregal AL, et al. Leukotriene receptor antagonists (montelukast) in the treatment of asthma crisis: preliminary results of a double-blind placebo controlled randomized study. Allerg Immunol (Paris). 2001;33(8):315–318. .
   PubMedGoogle Scholar
• Adachi M, Taniguchi H, Tohda Y, et al. The efficacy and tolerability of intravenous montelukast in acute asthma exacerbations in Japanese patients. J Asthma. 2012;49(6):649–656.
   PubMed Web of Science ®Google Scholar
• Morris CR, Becker AB, Pinieiro A, et al. A randomized, placebo-controlled study of intravenous montelukast in children with acute asthma. Ann Allergy Asthma Immunol. 2010;104(2):161–171.
   PubMed Web of Science ®Google Scholar
• Todi VK, Lodha R, Kabra SK. Effect of addition of single dose of oral montelukast to standard treatment in acute moderate to severe asthma in children between 5 and 15 years of age: a randomised, double-blind, placebo controlled trial. Arch Dis Child. 2010;95(7):540–543.
   PubMed Web of Science ®Google Scholar
• Zubairi AB, Salahuddin N, Khawaja A, et al. A randomized, double-blind, placebo-controlled trial of oral montelukast in acute asthma exacerbation. BMC Pulm Med. 2013;13:20.
   PubMed Web of Science ®Google Scholar
• Johnson D, Osborn LM. Cough variant asthma: a review of the clinical literature. J Asthma. 1991;28(2):85–90.
   PubMed Web of Science ®Google Scholar
• Niimi A. Cough, asthma, and cysteinyl-leukotrienes. Pulm Pharmacol Ther. 2013;26(5):514–519.
   PubMed Web of Science ®Google Scholar
• Spector SL, Tan RA. Effectiveness of montelukast in the treatment of cough variant asthma. Ann Allergy Asthma Immunol. 2004;93(3):232–236.
   PubMed Web of Science ®Google Scholar
• Kita T, Fujimura M, Ogawa H, et al. Antitussive effects of the leukotriene receptor antagonist montelukast in patients with cough variant asthma and atopic cough. Allergol Int. 2010;59(2):185–192.
   PubMedGoogle Scholar
• Takemura M, Niimi A, Matsumoto H, et al. Clinical, physiological and anti-inflammatory effect of montelukast in patients with cough variant asthma. Respiration Inter Rev Thoracic Dis. 2012;83(4):308–315.
   Web of Science ®Google Scholar
• Pickles RJ, DeVincenzo JP. Respiratory syncytial virus (RSV) and its propensity for causing bronchiolitis. J Pathol. 2015;235(2):266–276.
   PubMed Web of Science ®Google Scholar
• Tahan F, Celik S, Eke Gungor H. Effect of montelukast on clinical score and cytokine levels of infants for clinically diagnosed acute bronchiolitis. Allergol Immunopathol (Madr). 2015;43(4):376–382.
   PubMed Web of Science ®Google Scholar
• Li J, Pan JH. [Clinical efficacy of montelukast for the treatment of bronchiolitis in infants]. Zhongguo dang dai er ke za zhi = Chin J Contem Pediatr. 2015;17(10):1062–1065.
   PubMedGoogle Scholar
• Bisgaard H, Study Group on M, Respiratory Syncytial V. A randomized trial of montelukast in respiratory syncytial virus postbronchiolitis. Am J Respir Crit Care Med. 2003;167(3):379–383.
   PubMed Web of Science ®Google Scholar
• Nanulescu M, Popescu L, Farcau M, et al. [The effectiveness of montelukast in recurrent post-bronchiolitis wheezing]. Pneumologia. 2003;52(3–4):213–216.
   PubMedGoogle Scholar
• Zedan M, Gamil N, El-Assmy M, et al. Montelukast as an episodic modifier for acute viral bronchiolitis: a randomized trial. Allergy Asthma Proc. 2010;31(2):147–153.
   PubMed Web of Science ®Google Scholar
• Amirav I, Luder AS, Kruger N, et al. A double-blind, placebo-controlled, randomized trial of montelukast for acute bronchiolitis. Pediatrics. 2008;122(6):e1249–e1255.
   PubMed Web of Science ®Google Scholar
• Bisgaard H, Flores-Nunez A, Goh A, et al. Study of montelukast for the treatment of respiratory symptoms of post-respiratory syncytial virus bronchiolitis in children. Am J Respir Crit Care Med. 2008;178(8):854–860.
   PubMed Web of Science ®Google Scholar
• Proesmans M, Sauer K, Govaere E, et al. Montelukast does not prevent reactive airway disease in young children hospitalized for RSV bronchiolitis. Acta Paediatr. 2009;98(11):1830–1834.
   PubMed Web of Science ®Google Scholar
• Sundaresan S. Bronchiolitis obliterans. Semin Thorac Cardiovasc Surg. 1998;10(3):221–226.
   PubMedGoogle Scholar
• Yu J. Postinfectious bronchiolitis obliterans in children: lessons from bronchiolitis obliterans after lung transplantation and hematopoietic stem cell transplantation. Korean J Pediatr. 2015;58(12):459–465.
   PubMedGoogle Scholar
• Williams KM, Cheng GS, Pusic I, et al. Fluticasone, azithromycin, and montelukast treatment for new-onset bronchiolitis obliterans syndrome after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2016;22(4):710–716.
   PubMed Web of Science ®Google Scholar
• Verleden GM, Verleden SE, Vos R, et al. Montelukast for bronchiolitis obliterans syndrome after lung transplantation: a pilot study. Transpl Int. 2011;24(7):651–656.
   PubMed Web of Science ®Google Scholar
• Norman BC, Jacobsohn DA, Williams KM, et al. Fluticasone, azithromycin and montelukast therapy in reducing corticosteroid exposure in bronchiolitis obliterans syndrome after allogeneic hematopoietic SCT: a case series of eight patients. Bone Marrow Transplant. 2011;46(10):1369–1373. .
   PubMed Web of Science ®Google Scholar
• Camargo CA Jr., Boulet LP, Sutherland ER, et al. Body mass index and response to asthma therapy: fluticasone propionate/salmeterol versus montelukast. J Asthma. 2010;47(1):76–82.
   PubMed Web of Science ®Google Scholar
• Price D, Popov TA, Bjermer L, et al. Effect of montelukast for treatment of asthma in cigarette smokers. J Allergy Clin Immunol. 2013;131(3):763–771.
   PubMed Web of Science ®Google Scholar
• Papadopoulos NG, Philip G, Giezek H, et al. The efficacy of montelukast during the allergy season in pediatric patients with persistent asthma and seasonal aeroallergen sensitivity. J Asthma. 2009;46(4):413–420.
   PubMed Web of Science ®Google Scholar
• Meltzer EO, Malmstrom K, Lu S, et al. Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: a randomized, placebo-controlled clinical trial. J Allergy Clin Immunol. 2000;105(5):917–922.
   PubMed Web of Science ®Google Scholar
• Wilson AM, Orr LC, Sims EJ, et al. Effects of monotherapy with intra-nasal corticosteroid or combined oral histamine and leukotriene receptor antagonists in seasonal allergic rhinitis. Clin Exp Allergy. 2001;31(1):61–68.
   PubMed Web of Science ®Google Scholar
• van Adelsberg J, Philip G, LaForce CF, et al. Randomized controlled trial evaluating the clinical benefit of montelukast for treating spring seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2003;90(2):214–222.
   PubMed Web of Science ®Google Scholar
• Ratner PH, Howland WC 3rd, Arastu R, et al. Fluticasone propionate aqueous nasal spray provided significantly greater improvement in daytime and nighttime nasal symptoms of seasonal allergic rhinitis compared with montelukast. Ann Allergy Asthma Immunol. 2003;90(5):536–542.
   PubMed Web of Science ®Google Scholar
• Lu S, Malice MP, Dass SB, et al. Clinical studies of combination montelukast and loratadine in patients with seasonal allergic rhinitis. J Asthma. 2009;46(9):878–883.
   PubMed Web of Science ®Google Scholar
• Korn D, Van den Brande P, Potvin E, et al. Efficacy of add-on montelukast in patients with non-controlled asthma: a Belgian open-label study. Curr Med Res Opin. 2009;25(2):489–497. .
   PubMed Web of Science ®Google Scholar
• Kern EB, Sherris D, Stergiou AM, et al. Diagnosis and treatment of chronic rhinosinusitis: focus on intranasal Amphotericin B. Ther Clin Risk Manag. 2007;3(2):319–325.
   PubMedGoogle Scholar
• Wilson AM, White PS, Gardiner Q, et al. Effects of leukotriene receptor antagonist therapy in patients with chronic rhinosinusitis in a real life rhinology clinic setting. Rhinology. 2001;39(3):142–146. .
   PubMed Web of Science ®Google Scholar
• Yelverton JC, Holmes TW, Johnson CM, et al. Effectiveness of leukotriene receptor antagonism in the postoperative management of chronic rhinosinusitis. Int Forum Allergy Rhinol. 2016;6(3):243–247.
   PubMed Web of Science ®Google Scholar
• Nonaka M, Sakanushi A, Kusama K, et al. One-year evaluation of combined treatment with an intranasal corticosteroid and montelukast for chronic rhinosinusitis associated with asthma. J Nippon Med Sch. 2010;77(1):21–28.
   PubMedGoogle Scholar
• Wilson AM, Dempsey OJ, Sims EJ, et al. A comparison of topical budesonide and oral montelukast in seasonal allergic rhinitis and asthma. Clin Exp Allergy. 2001;31(4):616–624.
   PubMed Web of Science ®Google Scholar
• Philip G, Nayak AS, Berger WE, et al. The effect of montelukast on rhinitis symptoms in patients with asthma and seasonal allergic rhinitis. Curr Med Res Opin. 2004;20(10):1549–1558.
   PubMed Web of Science ®Google Scholar
• Virchow JC, Bachert C. Efficacy and safety of montelukast in adults with asthma and allergic rhinitis. Respir Med. 2006;100(11):1952–1959.
   PubMed Web of Science ®Google Scholar
• Pacheco Y, Freymond N, Devouassoux G. Impact of montelukast on asthma associated with rhinitis, and other triggers and co-morbidities. J Asthma. 2014;51(1):1–17.
   PubMed Web of Science ®Google Scholar
• Katial RK, Oppenheimer JJ, Ostrom NK, et al. Adding montelukast to fluticasone propionate/salmeterol for control of asthma and seasonal allergic rhinitis. Allergy Asthma Proc. 2010;31(1):68–75.
   PubMed Web of Science ®Google Scholar
• Cheng H, Leff JA, Amin R, et al. Pharmacokinetics, bioavailability, and safety of montelukast sodium (MK-0476) in healthy males and females. Pharm Res. 1996;13(3):445–448.
   PubMed Web of Science ®Google Scholar
• Storms W, Michele TM, Knorr B, et al. Clinical safety and tolerability of montelukast, a leukotriene receptor antagonist, in controlled clinical trials in patients aged > or = 6 years. Clin Exp Allergy. 2001;31(1):77–87.
   PubMed Web of Science ®Google Scholar
• Cobb DB, Abbott CL, Watson WA, et al. High-dose montelukast exposures in a 3-year-old and a 5-year-old child. Vet Hum Toxicol. 2002;44(2):91–92.
   PubMedGoogle Scholar
• Wechsler ME, Garpestad E, Flier SR, et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast. JAMA. 1998;279(6):455–457.
   PubMed Web of Science ®Google Scholar
• Knoell DL, Lucas J, Allen JN. Churg-Strauss syndrome associated with zafirlukast. Chest. 1998;114(1):332–334.
   PubMed Web of Science ®Google Scholar
• Franco J, Artés MJ. Pulmonary eosinophilia associated with montelukast. Thorax. 1999;54(6):558–560.
   PubMed Web of Science ®Google Scholar
• Wechsler ME, Finn D, Gunawardena D, et al. Churg-Strauss syndrome in patients receiving montelukast as treatment for asthma. Chest. 2000;117(3):708–713.
   PubMed Web of Science ®Google Scholar
• Tuggey JM, Hosker HS. Churg-Strauss syndrome associated with montelukast therapy. Thorax. 2000;55(9):805–806. .
   PubMed Web of Science ®Google Scholar
• Hammer HB, Aukrust P, Froland SS. [Churg-Strauss syndrome after treatment with Singulair (montelukast)]. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke. 2002;122(5):484–486.
   PubMedGoogle Scholar
• Solans R, Bosch JA, Selva A, et al. Montelukast and Churg-Strauss syndrome. Thorax. 2002;57(2):183–185.
   PubMed Web of Science ®Google Scholar
• Aypak C, Turedi O, Solmaz N, et al. A rare adverse effect of montelukast treatment: ecchymosis. Respir Care. 2013;58(9):e104–e106.
   PubMedGoogle Scholar
• Kocyigit A, Gulcan Oksuz B, Yarar F, et al. Hallucination development with montelukast in a child with asthma: case presentation. Iran J Allergy Asthma Immunol. 2013;12(4):397–399.
   PubMed Web of Science ®Google Scholar
• Alkhuja S, Gazizov N, Alexander ME. Sleeptalking! Sleepwalking! Side effects of montelukast. Case Rep Pulmonol. 2013;813786:2013.
   Google Scholar
• Minciullo PL, Saija A, Bonanno D, et al. Montelukast-induced generalized urticaria. Ann Pharmacother. 2004;38(6):999–1001.
   PubMed Web of Science ®Google Scholar
• Zaid AN, Mousa A, Ghazal N, et al. Interchangeability and comparative effectiveness between generic and brand montelukast immediate release tablets after a single oral administration in healthy volunteers. Clin Transl Allergy. 2015;5:37.
   PubMedGoogle Scholar
• Ghorwade VPA, Patil S, Srikonda K, et al. Development and evaluation of fast-dissolving film of montelukast sodium. WJMPBS. 2011;1(1):06–12.
   Google Scholar
• Cingi C, Toros SZ, Gürbüz MK, et al. Effect of grapefruit juice on bioavailability of montelukast. Laryngoscope. 2013;123(4):816–819.
   PubMed Web of Science ®Google Scholar
• Leibovitch ER, Deamer RL, Sanderson LA. Food-drug interactions: careful drug selection and patient counseling can reduce the risk in older patients. Geriatrics. 2004;59(3):19–22, 32–13.
   Google Scholar
• Mallhi TH, Sarriff A, Adnan AS, et al. Effect of fruit/vegetable-drug interactions on CYP450, OATP and p-glycoprotein: a systematic review. Trop J Pharm Res. 2015;14(10):1927–1935.
   Web of Science ®Google Scholar
• Mou-Ze Liu, Yue-Li Zhang, Mei-Zi Zeng, et al. Pharmacogenomics and herb-drug interactions: merge of future and tradition. Evid-Based Complement Alternat Med. 2015;2015:8. Article ID 321091. doi:10.1155/2015/321091.
   Google Scholar
• Deepalakshmi M, Arun K, Ahuja S. Grapefruit and medications may be a deadly mix – an overview. J Pharm BioSci. 2014;3:80–84.
   Google Scholar
• Mougey E, Lang J, Wen X, et al. Effect of citrus juice and SLCO2B1 genotype on the pharmacokinetics of montelukast. J Clin Pharmacol. 2011;51(5):751–760.
   PubMed Web of Science ®Google Scholar
• Kanjanawart S, Gaysonsiri D, Tangsucharit P, et al. Comparative bioavailability of two sildenafil tablet formulations after single-dose administration in healthy Thai male volunteers. Int J Clin Pharmacol Ther. 2011;49:8.
   Web of Science ®Google Scholar
• Zheng R, Kim B. Pharmacokinetics and bioequivalence of montelukast granules and montelukast tablets in Korean healthy volunteers. Int J Clin Pharmacol Ther. 2014;52:530–536.
   PubMed Web of Science ®Google Scholar
• Damle B, Duczynski G, Jeffers BW, et al. Pharmacokinetics of a novel orodispersible tablet of sildenafil in healthy subjects. Clin Ther. 2014;36(2):236–244.
   PubMed Web of Science ®Google Scholar
• Scaparrotta A, Di Pillo S, Attanasi M, et al. Montelukast versus inhaled corticosteroids in the management of pediatric mild persistent asthma. Multidiscip Respir Med. 2012;7(1):1.
   PubMed Web of Science ®Google Scholar
• Muñoz E, Ocampo DH, Espinal EE, et al. Bioequivalence study of two 10 mg montelukast immediate-release tablets formulations: a randomized, single-dose, open-label, two periods, crossover study. J Bioequiv Availab. 2014;2014:86–90.
   Google Scholar
• Sripalakit P, Maphanta S, Saraphanchotiwitthaya A. Bioequivalence study of two generic formulations of 10 mg montelukast tablets in healthy Thai male volunteers. Int J Clin Pharmacol Ther. 2010;48(9):628–632.
   PubMed Web of Science ®Google Scholar
• Hayashi H. [Personalized drug therapy-directed clinical pharmacology research based on genetic polymorphisms and pharmacokinetics analysis]. Yakugaku zasshi: J Pharm Soc Japan. 2013;133(10):1079–1085.
   PubMed Web of Science ®Google Scholar
• Szefler SJ, Martin RJ. Lessons learned from variation in response to therapy in clinical trials. J Allergy Clin Immunol. 2010;125(2):285–292; quiz 293–284.
   Web of Science ®Google Scholar
• Zedan M, Attia G, Zedan MM, et al. Clinical asthma phenotypes and therapeutic responses. ISRN Pediatrics. 2013;824781:2013.
   Google Scholar
• Portelli M, Sayers I. Genetic basis for personalized medicine in asthma. Expert Rev Respir Med. 2012;6(2):223–236.
   PubMed Web of Science ®Google Scholar
• Duroudier NP, Tulah AS, Sayers I. Leukotriene pathway genetics and pharmacogenetics in allergy. Allergy. 2009;64(6):823–839.
   PubMed Web of Science ®Google Scholar
• Drazen JM, Yandava CN, Dube L, et al. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nat Genet. 1999;22(2):168–170.
   PubMed Web of Science ®Google Scholar
• Tantisira KG, Lima J, Sylvia J, et al. 5-Lipoxygenase pharmacogenetics in asthma: overlap with Cys-leukotriene receptor antagonist loci. Pharmacogenet Genomics. 2009;19(3):244–247.
   PubMed Web of Science ®Google Scholar
• Lima JJ, Zhang S, Grant A, et al. Influence of leukotriene pathway polymorphisms on response to montelukast in asthma. Am J Respir Crit Care Med. 2006;173(4):379–385.
   PubMed Web of Science ®Google Scholar
• Klotsman M, York TP, Pillai SG, et al. Pharmacogenetics of the 5-lipoxygenase biosynthetic pathway and variable clinical response to montelukast. Pharmacogenet Genomics. 2007;17(3):189–196.
   PubMed Web of Science ®Google Scholar
• York TP, Vargas-Irwin C, Anderson WH, et al. Asthma pharmacogenetic study using finite mixture models to handle drug-response heterogeneity. Pharmacogenomics. 2009;10(5):753–767.
   PubMed Web of Science ®Google Scholar
• Lima JJ. Treatment heterogeneity in asthma: genetics of response to leukotriene modifiers. Mol Diagn Ther. 2007;11(2):97–104.
   PubMed Web of Science ®Google Scholar
• Mougey EB, Feng H, Castro M, et al. Absorption of montelukast is transporter mediated: a common variant of OATP2B1 is associated with reduced plasma concentrations and poor response. Pharmacogenet Genomics. 2009;19(2):129–138.
   PubMed Web of Science ®Google Scholar
• Dahlin A, Litonjua A, Lima JJ, et al. Genome-Wide Association Study identifies novel pharmacogenomic loci for therapeutic response to montelukast in asthma. Plos One. 2015;10(6):e0129385.
   PubMed Web of Science ®Google Scholar
• Tantisira KG, Drazen JM. Genetics and pharmacogenetics of the leukotriene pathway. J Allergy Clin Immunol. 2009;124(3):422–427.
   PubMed Web of Science ®Google Scholar
• Laidlaw TM, Boyce JA. Pathogenesis of aspirin-exacerbated respiratory disease and reactions. Immunol Allergy Clin North Am. 2013;33(2):195–210.
   PubMed Web of Science ®Google Scholar
• Shrestha Palikhe N, Kim SH, Jin HJ, et al. Genetic mechanisms in aspirin-exacerbated respiratory disease. J Allergy. 2012;2012:794890.
   Google Scholar
• Kim SH, Oh JM, Kim YS, et al. Cysteinyl leukotriene receptor 1 promoter polymorphism is associated with aspirin-intolerant asthma in males. Clin Exp Allergy. 2006;36(4):433–439.
   PubMed Web of Science ®Google Scholar
• Choi JH, Park HS, Oh HB, et al. Leukotriene-related gene polymorphisms in ASA-intolerant asthma: an association with a haplotype of 5-lipoxygenase. Hum Genet. 2004;114(4):337–344.
   PubMed Web of Science ®Google Scholar
• Park JS, Chang HS, Park CS, et al. Association analysis of cysteinyl-leukotriene receptor 2 (CYSLTR2) polymorphisms with aspirin intolerance in asthmatics. Pharmacogenet Genomics. 2005;15(7):483–492.
   PubMed Web of Science ®Google Scholar
• Lambert L. Montelukast in the treatment of asthma. SA Pharm J. 2013;81(1):22–24.
   Google Scholar
• Yelverton JC, Holmes TW, Johnson CM, et al. Effectiveness of leukotriene receptor antagonism in the postoperative management of chronic rhinosinusitis. Int Forum Allergy Rhinol. 2016;6(3):243–247. doi:10.1002/alr.21649.
   Google Scholar
• Williams KM, Cheng G-S, Pusic I, et al. Fluticasone, azithromycin, and montelukast treatment for new-onset bronchiolitis obliterans syndrome after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2016; 22(4):710–716.
   Web of Science ®Google Scholar
• Ertugay CK, Cingi C, Yaz A, et al. Effect of combination of montelukast and levocetirizine on otitis media with effusion: a prospective, placebo-controlled trial. Acta Otolaryngol. 2013;133(12):1266–1272.
   PubMed Web of Science ®Google Scholar
• Calapai G, Casciaro M, Miroddi M, et al. Montelukast-induced adverse drug reactions: a review of case reports in the literature. Pharmacology. 2014;94(1–2):60–70.
   PubMed Web of Science ®Google Scholar